Rx Price Clusters Parallel Managed Care Premiums, AstraZeneca Exec Says

Deeply discounted launch prices for brand name pharmaceuticals are rare because promotional costs are high regardless of price, AstraZeneca Director of Public Policy Robert Freeman, PhD, suggested during the HHS conference on drug pricing Aug. 8 in Washington, D.C.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet